An immediate application of such a biomarker in oncology is to optimise patient selection, wherein only those patients predicted to benefit most are enrolled into the clinical trial, i.e. in this example patients with HER2/neu positive gastric cancer are most likely to respond to trastuzumab therapy [87]. This evidence concerns the gene ERBB2 and gastric cancer.